SITC Updates

Immune Monitor August 2026 - Special Interest Groups

By Thomas Martin posted yesterday
A Message from the President One of the most exciting aspects of our field is seeing how advances in cancer immunotherapy continue to translate into new possibilities for patients. Recent preliminary results with a personalized cancer vaccine for melanoma are particularly exciting, demonstrating the potential of tailoring an immune response to the unique targets in an individual patient’s tumor. While further follow-up and validation will be important, these findings offer another reminder of the remarkable potential of immunotherapy and of how rational immunotherapy combinations can be better than monotherapy. One of the greatest strengths of ...

JITC Digest August 2026

By JITC Publications posted 5 days ago
JITC Digest – August 2026 In This Issue: Letter from the Editor | JITC Editor Picks | Popular Articles Hello JITC Readers, How time flies and the summer abates! I would like to highlight SITC 2026 and the early registration discount deadline coming up soon on August 24. I would encourage those who are still considering going, to register for the annual meeting, this year in Phoenix, Arizona and virtually from Nov. 4–8, 2026. Where are we heading in Immuno-Oncology (IO)? It is remarkable to see how far we have come in treating patients with cancer, no longer embarrassed to speak about true cures ...

Society for Immunotherapy of Cancer Forward Fund Announces 2026 Fellowship Recipients, Awarding $150,000 to Support the Next Generation of Cancer Immunotherapy Researchers

By SITC Communications posted 15 days ago
Reinforcing its commitment to advancing cancer immunotherapy through research and education, the Society for Immunotherapy of Cancer (SITC) Forward Fund is pleased to announce the recipients of its 2026 fellowships. This year's awards provide $150,000 in funding to support exceptional early career investigators whose innovative research has the potential to accelerate progress and improve outcomes for patients with cancer. "Every advance in cancer immunotherapy begins with researchers willing to ask bold questions and pursue new possibilities," said SITC Vice President Sandra Demaria, MD. "By investing in exceptional early career investigators, the Forward ...

Society for Immunotherapy of Cancer Announces 2026 Annual Award Recipients

By SITC Communications posted 22 days ago
The Society for Immunotherapy of Cancer (SITC) is pleased to announce the recipients of its 2026 Annual Awards, recognizing individuals whose exceptional leadership, scientific achievements and service have helped advance the field of cancer immunotherapy. The honorees will be recognized during the SITC 2026 Annual Meeting , taking place Nov. 4–8, 2026, at the Phoenix Convention Center in Phoenix, AZ and virtually. "The remarkable achievements of this year's award recipients reflect the innovation, collaboration and dedication that continue to transform cancer immunotherapy," said SITC Vice President Sandra Demaria, MD. "Their contributions have advanced ...

Immune Monitor - July 2026

By SITC Communications posted 27 days ago
A Message from the President As cancer immunotherapy continues to transform patient care, the next era of innovation will depend on our collective ability to develop the therapies that will define the future of the field. At SITC, we are committed to accelerating immunotherapy drug development by creating opportunities for collaboration, advancing scientific exchange and bringing together the diverse stakeholders needed to move promising discoveries from the laboratory to patients. This commitment is reflected in our #SITCQuestfor100 initiative , which challenges the field to achieve 100 novel immunotherapy agents by 2034. Achieving this goal will require ...

SITC Announces EU Immuno-oncology Drug Development Summit - Bringing the European IO Community Together to Foster the Next Wave of IO Therapeutics

By Thomas Martin posted 07-22-2026
Keynote Address featuring Dr. E. John Wherry – “Intersection of IO and Autoimmunity” MILWAUKEE, WI – The Society for Immunotherapy of Cancer (SITC) is proud to announce the upcoming EU Immuno-oncology Drug Development Summit, taking place in Lausanne, Switzerland on Sept. 3–4, 2026, at the Agora Cancer Research Center. As the world’s leading member-driven society dedicated to professionals working in cancer immunotherapy, SITC is uniquely positioned to bring together the entire immuno-oncology ecosystem. The EU Immuno-oncology Drug Development Summit will facilitate understanding, open dialogue, and exploration of best practices for modern immuno-oncology ...

SITC and CRI Launch Annual Collaboration Bringing the Prestigious CRI William B. Coley Award Lecture to the SITC Annual Meeting

By Thomas Martin posted 07-21-2026
NK cell pioneer Éric Vivier, DVM, PhD, to deliver the inaugural lecture at SITC 2026 MILWAUKEE, WI – The Society for Immunotherapy of Cancer (SITC) and t he Cancer Research Institute (CRI) are proud to announce the CRI William B. Coley Award Lecture will be presented at the 41 st Annual Meeting and Pre-Conference Programs (SITC 2026), reflecting the shared commitment of both organizations to celebrating scientific excellence at the world's leading forum dedicated exclusively to cancer immunotherapy. Éric Vivier, DVM, PhD, holder of the Natural Killer (NK) Cell Chair of the Fondation Gustave Roussy, will deliver the CRI William ...

JITC Digest July 2026

By JITC Publications posted 07-15-2026
INSIDE THIS ISSUE: Letter from the Editor| JITC Editor Picks|New Special Series Myeloid Cells in Immuno-Oncology| JITC Meet-the-Editor Seession at JACI (Japan)| Popular Articles Letter from the Editor Hello JITC Readers, This month I would like to call attention to the recently completed “ Myeloid Cells in Immuno-Oncology ” special series now out in JITC . We also have several exciting series in the works which will be appearing over the next few months, including ones on AI in IO and neurobiology/immunobiology intersections. Myeloid Cells in Cancer Immunology Cancer in adults (but not ...

Oncology News Burst from the FDA: FDA Approves Pembrolizumab or Pembrolizumab and Berahyaluronidase Alfa-pmph Each with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer

By SITC Communications posted 07-13-2026
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position on the safety or efficacy of the product or therapy described. ...

SITC Raises Concerns About Proposed Changes to Federal Grant-Making Rules

By SITC Advocacy posted 07-07-2026
The Society for Immunotherapy of Cancer (SITC) has submitted comments to the Office of Management and Budget (OMB) regarding proposed changes to the regulations governing Federal Financial Assistance . View the comments in their entirety at this LINK . For decades, independent scientific peer review has ensured that federal research funding is awarded based on scientific merit, innovation, and potential patient benefit. This merit-based system has helped drive groundbreaking advances in cancer research and established the United States as a global leader in biomedical innovation. SITC is concerned that the proposed rule could reduce the role ...

Oncology News Burst from the FDA: FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor Hematopoietic Stem Cell Transplantation for Adults with Hematologic Malignancies

By SITC Communications posted 07-01-2026
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position on the safety or efficacy of the product or therapy described. ...

Immune Monitor - June 2026

By SITC Communications posted 07-01-2026
A Message from the President As Cancer Immunotherapy Awareness Month comes to a close, I’m reflecting on the remarkable progress and momentum in the field of cancer immuno-oncology. Throughout June, our community celebrated the scientific advances, collaboration and innovation that are shaping the future of cancer treatment, and I am proud of the many ways SITC helped elevate and support these important conversations. Just last week, SITC hosted the 2026 Biotech Strategic Meeting at the New York Stock Exchange, where we set the stage for critical conversations on investing, financing, international drug development and other strategic considerations ...

Oncology News Burst from the FDA: FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination with Pembrolizumab for First-Line Treatment of Triple-Negative Breast Cancer

By SITC Communications posted 06-30-2026
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position on the safety or efficacy of the product or therapy described. ...

Oncology News Burst from the FDA: FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of renal cell carcinoma

By SITC Communications posted 06-29-2026
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position on the safety or efficacy of the product or therapy described. ...

JITC Digest June 2026

By JITC Publications posted 06-17-2026
INSIDE THIS ISSUE: Letter from the Editor| JITC Editor Picks|SITC 40 th Anniversary Special Series| Popular Articles Letter from the Editor Hello JITC Readers, June is Cancer Immunotherapy Month—a time to celebrate the remarkable progress our field has achieved and recommit ourselves to the work that remains. As we celebrate this month, I am delighted to share JITC’s new 2025 Impact Factor of 11.7—an outstanding achievement that shows the continued strength, influence, and growth of our journal, and places JITC among the top 5% of all immunology journals and the top 9% of all oncology journals. It ...

2026 ASCO Annual Meeting Scientific Highlights - June 2

By Thomas Martin posted 06-03-2026
We are pleased to present highlights of the latest advances in immunotherapy emerging from the 2026 ASCO Annual Meeting, June 2, 2026. (Thanks to Chinmay Jani, MD and Terri Holzen, PhD for compiling these scientific highlights) Fitness-enhanced CEA-targeting CAR T cells for advanced colorectal cancer with peritoneal metastases 3514. Phase 1 study of intraperitoneal fast-manufactured IL-9-secreting CEACAM5-targeted CAR T cells in advanced colorectal cancer with peritoneal metastases Hangyu Zhang (The First Affiliate Hospital, Zhejiang University School of Medicine, Hangzhou, China) presented safety and preliminary efficacy data from ...

2026 ASCO Annual Meeting Scientific Highlights - June 1

By Thomas Martin posted 06-02-2026
We are pleased to present highlights of the latest advances in immunotherapy emerging from the 2026 ASCO Annual Meeting, June 1, 2026. (Thanks to Chinmay Jani, MD and Terri Holzen, PhD for compiling these scientific highlights) Live biotherapeutic CBM588 improves the clinical efficacy of immune checkpoint blockade-based therapies as first-line treatment for metastatic renal cell carcinoma 4519. Microbial dysbiosis as predictor of benefit from CBM588 as an adjunct to immune checkpoint blockade-based first line therapies in metastatic renal cell carcinoma Rahul Winayak (City of Hope Comprehensive Cancer Center, Duarte, ...

2026 ASCO Annual Meeting Scientific Highlights - May 31

By Thomas Martin posted 06-01-2026
We are pleased to present highlights of the latest advances in immunotherapy emerging from the 2026 ASCO Annual Meeting, May 31, 2026. (Thanks to Chinmay Jani, MD and Terri Holzen, PhD for compiling these scientific highlights) Final safety, efficacy and biomarker results from the first-in-human study of oncolytic virus RP2 alone and in combination with nivolumab for advanced solid tumors 2504. RP2 oncolytic immunotherapy alone and in combination with nivolumab (nivo) in patients with advanced solid tumors: Final safety, efficacy, and biomarker results from the phase 1 first-in-human (FIH) study Joseph J. Sacco (The Clatterbridge ...

Immune Monitor - May 2026

By SITC Communications posted 06-01-2026
A Message from the President The pace of discovery in cancer immunotherapy continues to accelerate, creating both extraordinary opportunity and an urgent need for collaboration. For more than 40 years, the Society for Immunotherapy of Cancer (SITC) Annual Meeting has helped drive these conversations by convening the global immuno-oncology community around the latest advances in science, translational research, and clinical development. SITC 2026 , our 41 st Annual Meeting and Pre-Conference Programs, will be held Nov. 4̶–8 in Phoenix, AZ and virtually. SITC 2026 will bring together researchers, clinicians, government and industry leaders for an ...

2026 ASCO Annual Meeting Scientific Highlights - May 30

By Thomas Martin posted 05-31-2026
We are pleased to present highlights of the latest advances in immunotherapy emerging from the 2026 ASCO Annual Meeting, May 30, 2026. (Thanks to Chinmay Jani, MD and Terri Holzen, PhD for compiling these scientific highlights) Tumor-specific MHC-II as a prospective biomarker of response to perioperative chemoimmunotherapy for gastric cancer 2513. Perioperative tislelizumab plus chemotherapy versus chemotherapy in MHC-II positive /MHC-II negative locally advanced GC/GEJC: A prospective randomized, open-label, biomarker-driven, phase 2 trial Xiangdong Cheng, MD (Zhejiang Cancer Hospital, Hangzhou, Zhejiang Province, China) presented ...